For most of Medicare’s history, it would not pay for a drug used only for weight loss. That changed on July 1, 2026. A temporary federal program called the Medicare GLP-1 Bridge is now live, and eligible Part D members can get Wegovy, Zepbound (KwikPen), or Foundayo for a flat $50 a month — the first time these medications are within reach through Medicare for weight management.
This guide explains exactly who qualifies, the three BMI categories, how to get a prescription approved now that the program is running, and the four catches that the insurer and clinic pages tend to leave out. All figures come from the Centers for Medicare & Medicaid Services (CMS) and are current as of July 2026. SunnyPharma is an independent education site — we don’t sell, ship, or dispense medication.
The Medicare GLP-1 Bridge is live now. From its July 1, 2026 launch through December 31, 2027, eligible Medicare Part D members can get three weight-loss drugs — Wegovy, Zepbound (KwikPen), and Foundayo — for a flat $50 per month. You qualify based on your BMI and certain health conditions, and your provider can submit the prior authorization today. The program runs outside your regular Part D plan, and the $50 does not count toward your deductible or out-of-pocket cap.
- The Bridge is live as of July 1, 2026 — providers can submit prior authorizations now.
- Covers Wegovy (injection and tablets), Zepbound (KwikPen only), and Foundayo — for weight management, at a flat $50/month. You pay $50 of the $245 monthly net price; CMS pays the other $195.
- The $50 stays the same as your dose increases, but does not count toward your Part D deductible or out-of-pocket cap.
- Extra Help (the low-income subsidy) cannot be applied to Bridge prescriptions.
- Eligibility is based on the BMI you had when you started GLP-1 therapy — losing weight on the drug doesn’t disqualify you.
- If you have type 2 diabetes, sleep apnea, or fatty liver disease, you’re excluded — but standard Part D may already cover you for less.
- The program ends December 31, 2027. There is no guaranteed coverage after that yet.
What the Medicare GLP-1 Bridge Actually Is
For most of Medicare’s history, Part D was barred from paying for drugs used only for weight loss. The Medicare GLP-1 Bridge is a temporary federal demonstration that steps around that gap. It launched July 1, 2026 and runs through December 31, 2027, letting an eligible Part D beneficiary get one of three covered weight-loss medications for a flat $50 per 30-day supply.
The unusual part: it runs outside your normal Part D plan. Your plan doesn’t administer it and doesn’t have to opt in — a central processor (administered by Humana) handles the approvals, claims, and pharmacy payments nationwide. That means access doesn’t depend on whether your specific plan chose to cover GLP-1s.
Here’s what your $50 actually buys, in cost-transparency terms: manufacturers supply the covered drugs to the program at a negotiated net price of $245 per month. You pay $50 of that, and CMS pays the remaining $195. For comparison, list prices on these medications run over $1,000 a month without coverage — so the negotiated $245 is where most of the “discount” actually lives.
Which Drugs Are Covered — and Which Aren’t
The Bridge covers three products when prescribed for weight management: all formulations of Wegovy (the injection and the tablet), the KwikPen formulation of Zepbound, and the Foundayo tablet. The single-dose vial and single-dose pen versions of Zepbound are not on the Bridge.
Two drugs people expect to see are missing on purpose: Ozempic and Mounjaro carry diabetes indications, not weight-loss indications, so they’re handled under standard Part D, not the Bridge.
| Drug | Covered on Bridge? | Note |
|---|---|---|
| Wegovy (injection & tablets) | Yes — all formulations | For weight management |
| Zepbound (KwikPen) | Yes — KwikPen only | Single-dose vial/pen not covered |
| Foundayo (tablet) | Yes | For weight management |
| Ozempic | No | Diabetes indication — standard Part D |
| Mounjaro | No | Diabetes indication — standard Part D |
Who Qualifies: The Three BMI Categories
You must be at least 18, enrolled in a Part D or Medicare Advantage drug plan, and using the medication for chronic weight management alongside lifestyle changes. Beyond that, eligibility comes down to one of three BMI-and-health tiers:
- BMI 35 or higherQualifies on its own — no additional condition required.
- BMI 30 or higher + one conditionHeart failure (preserved ejection fraction), uncontrolled high blood pressure despite two or more medications, or chronic kidney disease stage 3a or above.
- BMI 27 or higher + one conditionPrediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Already on a GLP-1 and lost weight? You’re not disqualified. Eligibility is judged by the BMI you had when you first started GLP-1 therapy, not today’s number. If you began at a BMI of 37 and you’re now at 34, your prescriber attests that you met the threshold at initiation — even if you started before the Bridge launched or before you joined Medicare.
The Pharmacy “Denial” That Actually Means You’re In
This is the single most confusing part of the program, and it’s catching people off guard in the first days of the launch. The Bridge uses a required rejection step. Before your prescriber can submit the prior authorization, your pharmacy first transmits a claim to the Bridge network and receives a system rejection. That rejection isn’t a denial of your eligibility — it’s the trigger that opens the system so your doctor can submit your paperwork.
If the pharmacy says “denied,” don’t walk away. An initial counter rejection is often a normal, built-in step — not a final answer. Tell your prescriber to submit the Bridge prior authorization to the central processor. Approval comes after that, and then you fill at $50.
One more thing worth knowing: the Bridge has no formal appeals process. If a prior authorization is turned down, the fix is resubmission — your provider can resubmit the request as many times as needed, for example with corrected BMI documentation or condition codes.
The Catches the Insurer Pages Skip
The $50 figure is real, but four limits travel with it. An honest decision needs all four on the table.
| The catch | What it means for you |
|---|---|
| No deductible credit | The $50 does not count toward your Part D deductible. |
| No out-of-pocket credit | It does not count toward the annual Part D out-of-pocket cap, so it never “caps out.” |
| No Extra Help, no coupons | The low-income subsidy (Extra Help) cannot be applied, and manufacturer coupons can’t reduce the $50 further — even a $5–10 copay member pays the full $50. |
| Ends Dec 31, 2027 | Coverage is temporary. There’s no guaranteed Part D coverage after that yet, and weight regain after stopping is common. |
Have type 2 diabetes, sleep apnea, or fatty liver (MASH)? You may have a better route. Those diagnoses exclude you from the Bridge, but that’s usually good news: standard Medicare Part D already covers GLP-1 medications for type 2 diabetes, moderate-to-severe obstructive sleep apnea, and MASH — often below $50. Ask your plan about coverage under your regular Part D benefit first.
How to Get It, Step by Step
The program is accepting prior authorizations now — there’s no waiting list and no separate sign-up. CMS also launched a beneficiary eligibility checker at Medicare.gov/glp1bridge alongside the July 1 start.
- Confirm you’re enrolled in a Medicare Part D plan or a Medicare Advantage plan that includes drug coverage.
- See your provider. They confirm you meet one of the three BMI-and-health tiers and document weight-management counseling.
- Your provider submits a prior authorization request and prescription to the central processor — not your Part D plan. Submissions have been open since July 1, 2026.
- At the pharmacy, expect the system rejection first — it’s the green light, not a denial.
- Once approved, fill your prescription for the flat $50 copay. The price stays $50 even as your dose increases.
What Happens After 2027
The Bridge was first planned as a six-month stopgap before a larger program called BALANCE. That changed. In April 2026, CMS announced it would not launch BALANCE in Medicare in 2027 and instead extended the Bridge through December 31, 2027, while it collects data on how beneficiaries use these drugs.
If you read older pages still saying “BALANCE starts January 2027,” they’re out of date. For now, plan with your doctor as if coverage ends in 2027, because nothing past that date is guaranteed.
This program is Medicare-only. If you’re under 65 or uninsured, the Bridge won’t help you directly — see the weight-management hub for the self-pay and assistance routes that fit people without Medicare.
Frequently Asked Questions
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (FDA, CMS/Medicare, NIH, KFF), and manufacturer sources (NovoCare, Novo Nordisk). Cost and program details are drawn from official CMS program announcements, FDA safety communications, and published NovoCare pricing.
Read our editorial policy →Sources & References
- CMS — Medicare GLP-1 Bridge (overview, provider, pharmacy & Part D plan pages). 2026.
- CMS Newsroom — CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications. July 1, 2026.
- CMS Newsroom — Coming Soon: $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. May 2026.
- KFF — What to Know About the BALANCE Model and the Medicare GLP-1 Bridge. May 11, 2026.
- Becker’s Hospital Review — CMS launches the Medicare GLP-1 Bridge — but 4 questions linger. July 2026.
- NPR — Medicare to launch weight-loss drug option in July with $50 copay. May 6, 2026.
- National Council on Aging — Expanding Access to Weight-Loss Medications: The Medicare GLP-1 Bridge Program. 2026.